Indivior Pharmaceuticals, Inc. INDV Additional Paid-In Capital
Additional Paid-In Capital at other companies
Other financials
Where this comes from
Reported directly by Indivior Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:AdditionalPaidInCapital.
The official record: Indivior Pharmaceuticals, Inc. ’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →
Ask your AI about Indivior Pharmaceuticals, Inc. 's additional paid-in capital.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Indivior Pharmaceuticals, Inc. 's additional paid-in capital?
- Indivior Pharmaceuticals, Inc. (INDV) reported additional paid-in capital of $165M in Q1 2026.
- How has Indivior Pharmaceuticals, Inc. 's additional paid-in capital changed year-over-year?
- Indivior Pharmaceuticals, Inc. 's additional paid-in capital increased by 77.4% year-over-year, from $93M to $165M.
- What is the long-term trend for Indivior Pharmaceuticals, Inc. 's additional paid-in capital?
- Over 2 years (2023 to 2025), Indivior Pharmaceuticals, Inc. 's additional paid-in capital has grown at a 12.8% compound annual growth rate (CAGR), from $88M to $112M.
- What does additional paid-in capital mean?
- Capital received from shareholders in excess of par value — the premium investors paid over the nominal value of shares at issuance, plus stock-based compensation effects.